W Braam1, H Keijzer, H Struijker Boudier, R Didden, M Smits, L Curfs. 1. Department Advisium, 's Heeren Loo Zuid-Veluwe, Wekerom, The Netherlands Department of Clinical Chemistry, Rijnstate Hospital, Arnhem, The Netherlands Department of Pharmacology and Toxicology, Maastricht University, Maastricht, The Netherlands Special Education, Behavioural Science Institute, Radboud University Nijmegen, Nijmegen, The Netherlands Department of Neurology, Gelderse Vallei Hospital, Ede, The Netherlands Department of Clinical Genetics, University Maastricht/Academic Hospital, Maastricht, The Netherlands.
Abstract
BACKGROUND: In some of our patients with intellectual disabilities (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment. In these patients melatonin levels at noon were extremely high (>50 pg/ml). We hypothesise that the disappearing effectiveness is associated with slow metabolisation of melatonin because of a single nucleotide polymorphism (SNP) of CYP1A2. METHOD: In this pilot study we analysed DNA extracted from saliva samples of 15 consecutive patients with disappearing effectiveness of melatonin. Saliva was collected at noon and 4 pm for measuring melatonin levels. RESULTS: In all patients' salivary melatonin levels at noon were >50 or melatonin half time was > 5 h. A SNP was found in eight of 15 patients. The allele 1C was found in two patients and in six patients the 1F allele was found. CONCLUSIONS: Of 15 patients with disappearing effectiveness of melatonin, seven were diagnosed with autism spectrum disorder, and in four of them a SNP was found. The other eight patients were known with a genetic syndrome. In six of them behaviour was considered to be autistic-type and in three of them a SNP was found. This finding may give a new direction for research into the genetic background of autism.
BACKGROUND: In some of our patients with intellectual disabilities (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment. In these patientsmelatonin levels at noon were extremely high (>50 pg/ml). We hypothesise that the disappearing effectiveness is associated with slow metabolisation of melatonin because of a single nucleotide polymorphism (SNP) of CYP1A2. METHOD: In this pilot study we analysed DNA extracted from saliva samples of 15 consecutive patients with disappearing effectiveness of melatonin. Saliva was collected at noon and 4 pm for measuring melatonin levels. RESULTS: In all patients' salivary melatonin levels at noon were >50 or melatonin half time was > 5 h. A SNP was found in eight of 15 patients. The allele 1C was found in two patients and in six patients the 1F allele was found. CONCLUSIONS: Of 15 patients with disappearing effectiveness of melatonin, seven were diagnosed with autism spectrum disorder, and in four of them a SNP was found. The other eight patients were known with a genetic syndrome. In six of them behaviour was considered to be autistic-type and in three of them a SNP was found. This finding may give a new direction for research into the genetic background of autism.
Authors: S E Goldman; M L Alder; H J Burgess; B A Corbett; R Hundley; D Wofford; D B Fawkes; L Wang; M L Laudenslager; B A Malow Journal: J Autism Dev Disord Date: 2017-06
Authors: João Xavier Santos; Célia Rasga; Ana Rita Marques; Hugo Martiniano; Muhammad Asif; Joana Vilela; Guiomar Oliveira; Lisete Sousa; Ana Nunes; Astrid M Vicente Journal: Front Neurosci Date: 2022-05-19 Impact factor: 5.152
Authors: Olivia J Veatch; Julie S Pendergast; Melissa J Allen; Roberta M Leu; Carl Hirschie Johnson; Sarah H Elsea; Beth A Malow Journal: J Autism Dev Disord Date: 2015-01